



Clearbridge BioMedics' ClearCell™ CTChip® presented at the Molecular Med Tri-Conference

20 February 2012, San Francisco, USA – Clearbridge BioMedics' revolutionary ClearCell™ CTChip® will be presented at the Molecular Med Tri-Conference in San Francisco from 19 to 23 February 2012. Clearbridge BioMedics is partnering with Abnova to distribute its proprietary ClearCell™ System and CTChip®, which Abnova will be marketing as the Abnova Captor System along with its proprietary antibodies and reagents. This product will be showcased during the exhibition, where some 3,000 delegates will have the opportunity to view the Abnova Captor system.

The Abnova Captor system is a platform that provides the next generation, non-invasive liquid biopsy for cancer screening, staging, treatment and monitoring. It is driven by Clearbridge BioMedics' ClearCell™ CTChip®, an advanced micro-filtration system for isolating and retrieving circulating tumor cells, and also incorporates Abnova's proprietary antibody reagents, for accurately diagnosing specific medical conditions.

Clearbridge BioMedics partners with companies like Abnova, to distribute its proprietary ClearCell™ CTChip® technology. Clearbridge BioMedics will work with these partners to co-brand and co-market the device, allowing it to reach wider markets.

During the Molecular Med Tri-Conference, Clearbridge BioMedics' co-founder and inventor, Professor Lim Chwee Teck will be presenting the findings of his research in a talk entitled, "Microfluidic Biochips for the Label-Free Detection, Isolation and Retrieval of Circulating Tumor Cells". Prof Lim is from the Department of Bioengineering and Department of Mechanical Engineering, National University of Singapore.

About Clearbridge BioMedics Clearbridge BioMedics specializes in novel platforms with applications in oncology research and diagnostics. It is a National University of Singapore (NUS) spinoff company, that is committed to developing medical devices, which will impact the world and revolutionize cancer diagnostics and patient care, by leveraging on ground-breaking technology from research partners.

The ClearCell™ System comprises patent-pending CTChips®, which are microfluidic biochips able to effectively detect and isolate wholly-intact CTCs (Circulating Tumor Cells) from small quantities of patient blood samples. The isolated CTCs can then be stained directly on the CTChips® for identification and enumeration, or retrieved for further molecular analysis. The ClearCell™ System aims to be the next generation of non-invasive "liquid biopsy" approach for cancer screening, diagnosis, staging, personalised medication, and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America. (www.clearbridgebiomedics.com)

About Abnova Abnova is a biotech company specializing in high throughput monoclonal antibody production. The infrastructure Abnova has developed is a unique combination of world-class technologies and management experience of the IT industry in Taiwan. The company has vastly expanded the scope and availability of bio-tools reagents by taking a genome-wide approach to the production of human recombinant protein and antibody. Abnova has developed a portfolio of integrated and system applications including antibody pairs, ELISA kits, assays, and FISH probes which are essential to the biomarker discovery and translational research institutes. Abnova also has *in vitro* diagnostic programs focusing on diabetes, infection, and cancer, and fully human antibody therapeutic for the treatment of sepsis. (www.abnova.com)